Gentamicin fails to increase dystrophin expression in dystrophin‐deficient muscle
- 4 March 2003
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 27 (5) , 624-627
- https://doi.org/10.1002/mus.10341
Abstract
A recent report that aminoglycoside antibiotics restored the expression of functional dystrophin to skeletal muscles of mdx mice, a model of Duchenne muscular dystrophy (DMD), raised hopes that DMD may be treatable by a conventional drug. Subsequently, several human trials were initiated for evaluating gentamicin therapy in selected DMD patients. An increase of dystrophin expression was not detected in one human trial that was fully reported. Here, we report that we were unable to replicate previously published beneficial results by gentamicin treatment in the mdx mouse. Therefore, we believe that additional animal experimentation is required to further evaluate the possibility of in vivo aminoglycoside therapy of DMD. Muscle Nerve 27: 624–627, 2003Keywords
Funding Information
- Muscular Dystrophy Association (MDA)
- Muscular Dystrophy Association of Canada (MDAC)
- Deutsche Forschungsgemeinschaft (DFG)
- German Duchenne Parents Project (aktion benni und co.)
This publication has 19 references indexed in Scilit:
- Special Centennial Workshop – 101st ENMC International Workshop: Therapeutic Possibilities in Duchenne Muscular Dystrophy, 30th November–2nd December 2001, Naarden, The NetherlandsNeuromuscular Disorders, 2002
- When running a stop sign may be a good thingAnnals of Neurology, 2001
- Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutationsAnnals of Neurology, 2001
- Novel approaches to treat muscular dystrophiesExpert Opinion on Investigational Drugs, 2001
- Structural origins of aminoglycoside specificity for prokaryotic ribosomesJournal of Molecular Biology, 2001
- Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx miceJournal of Clinical Investigation, 1999
- Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) miceGene Therapy, 1998
- Genomic screening for beta-sarcoglycan gene mutations: missense mutations may cause severe limb-girdle muscular dystrophy type 2E (LGMD 2E)Human Molecular Genetics, 1996
- Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutationsNature Medicine, 1996
- Dystrophin predominantly localizes to the transverse tubule/Z-line regions of single ventricular myocytes and exhibits distinct associations with the membraneMolecular and Cellular Biochemistry, 1994